Boston, MA (PRWEB) February 26, 2014
Cambridge Biomedical Inc announces contract with major biotech for PK/PD biomarker assay development for the detection of phosphorylated histones utilizing Flow Cytometry. This technique also has many other applications for the detection of genetic damage caused by cytotoxic chemical agents, especially in the context of cancer treatment and therapy.
Cambridge Biomedical’s experience in bioanalytical assay development, optimization, validation and diagnostic testing coupled with their wide range of technology platforms was instrumental for the successful completion of negotiations.
Dr. John Reddington, COO of Cambridge Biomedical, commented that “Our scientific expertise, combined with our recent addition of Quality Assurance and Regulatory consulting to our menu of services, enables us to provide critical solutions; to meet the bioanalytical needs of our partners in the burgeoning healthcare community.”
Since 1997, Cambridge Biomedical has partnered with our clients by providing a diverse range of services from pre-clinical to post market. Including; assay development, optimization, validation and diagnostic testing. Conveniently located to support the Northeast pharmaceutical development market, yet with a national and global reach. Our personalized project management, approach along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensure we meet our client’s product development timelines